BF
CORT icon

BOK Financial’s Corcept Therapeutics CORT Stock Holding History

BOK Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Sell
23,938
-29,954
-56% -$1.81M 0.03% 322
2026
Q1 		$2.17M Buy
53,892
+23,396
+77% +$875K 0.03% 311
2025
Q4 		$1.06M Buy
+30,496
New +$2.4M 0.02% 414

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOK Financial's CORT Position: Q2 2026 in Review

BOK Financial reduced its Corcept Therapeutics (CORT) stake by 56% in Q2 2026, selling an estimated $1.81M and leaving 23,938 shares worth $2.08M. The position accounts for 0.03% of the portfolio, ranked #322.

BOK Financial first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.17M in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • BOK Financial held 23,938 shares of Corcept Therapeutics worth $2.08M as of Q2 2026.
  • BOK Financial sold 29,954 Corcept Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Corcept Therapeutics made up 0.03% of BOK Financial's portfolio in Q2 2026, its #322 holding.
  • BOK Financial first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • BOK Financial's Corcept Therapeutics position peaked at $2.17M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.